Tumor-educated platelet blood tests for Non-Small Cell Lung Cancer detection and management

Sci Rep. 2023 Jun 8;13(1):9359. doi: 10.1038/s41598-023-35818-w.

Abstract

Liquid biopsy approaches offer a promising technology for early and minimally invasive cancer detection. Tumor-educated platelets (TEPs) have emerged as a promising liquid biopsy biosource for the detection of various cancer types. In this study, we processed and analyzed the TEPs collected from 466 Non-small Cell Lung Carcinoma (NSCLC) patients and 410 asymptomatic individuals (controls) using the previously established thromboSeq protocol. We developed a novel particle-swarm optimization machine learning algorithm which enabled the selection of an 881 RNA biomarker panel (AUC 0.88). Herein we propose and validate in an independent cohort of samples (n = 558) two approaches for blood samples testing: one with high sensitivity (95% NSCLC detected) and another with high specificity (94% controls detected). Our data explain how TEP-derived spliced RNAs may serve as a biomarker for minimally-invasive clinical blood tests, complement existing imaging tests, and assist the detection and management of lung cancer patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Algorithms
  • Biomarkers, Tumor / genetics
  • Blood Platelets / metabolism
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Hematologic Tests
  • Humans
  • Lung Neoplasms* / genetics
  • RNA / metabolism

Substances

  • Biomarkers, Tumor
  • RNA